The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents
Abstract
Atopic dermatitis (AD) is an inflammatory skin disease that frequently occurs in adolescents. Although there are many treatment options, the challenge for clinicians is finding an effective long-term drug for AD with a favorable safety profile. The purpose of this review is to describe the role of tralokinumab, an IL-13 inhibitor, in treating adolescent AD. The clinical efficacy and safety of tralokinumab were established in clinical trials for adults with moderate-to-severe AD. Based on the results of these trials and the preliminary results of trials conducted on adolescents with AD, tralokinumab effectively alleviates symptoms with tolerable adverse effects. Extending the use of tralokinumab to adolescents with moderate-to-severe AD seems promising for the future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of atopic dermatitis targets epidermal barrier dysfunction and type 2 immune dysregulation.
“Treatment of atopic dermatitis targets the epidermal barrier dysfunction and type 2 immune dysregulation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
Emollients and ceramide-based moisturizers restore lipid composition, reduce transepidermal water loss, and limit allergen and microbial penetration.
“Management includes both barrier repair options and targeted immunomodulation, with emollients and ceramide-based moisturizers, which restore lipid composition, reduce transepidermal water loss, and limit allergen and microbial penetration.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
Topical corticosteroids and calcineurin inhibitors remain first-line treatments for atopic dermatitis, while topical JAK inhibitors provide targeted inhibition of cytokine signaling downstream of IL-4 and IL-13.
“Topical anti-inflammatory therapies, including corticosteroids and calcineurin inhibitors, remain first-line treatments, while topical JAK inhibitors provide targeted inhibition of cytokine signaling downstream of IL-4 and IL-13.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
Biologic therapies targeting type 2 inflammation, including dupilumab, lebrikizumab, and tralokinumab, have shown significant efficacy in moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling.
“Biologic therapies targeting type 2 inflammation, including dupilumab, lebrikizumab, and tralokinumab, have shown significant efficacy in moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling [11,12,13,14,15].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
These atopic dermatitis therapies reduce inflammation and contribute to restoration of barrier function.
“These therapies reduce inflammation and contribute to the restoration of barrier function.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
In moderate-to-severe atopic dermatitis, systemic immunosuppressants such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil can be used, alongside oral JAK inhibitors that interfere with intracellular signaling pathways central to disease pathogenesis.
“In moderate-to-severe disease, systemic immunosuppressants can be used, such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil, alongside oral JAK inhibitors that interfere with intracellular signaling pathways central to disease pathogenesis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [15]
Cites
Langan, S., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,943 · see citing works
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M. R., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 888 · see citing works
Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638 · see citing works
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516 · see citing works
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman‐Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 408 · see citing works
Silverberg, J. I., Toth, D., Bieber, T. R. M., Alexis, A. F., Elewski, B. E., Pink, A., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19573 · Cited by 330 · see citing works
Wollenberg, A., Kinberger, M., Arents, B. W. M., ASZODI, N., VALLE, G. L. A., Barbarot, S., Bieber, T. R. M., Brough, H. A., Calzavara‐Pinton, P., Christen-Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18429 · Cited by 304 · see citing works
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Simpson, E. L., Papp, K. A., Blauvelt, A., Chu, C., Hong, H., Katoh, N., Calimlim, B., Thyssen, J. P., Chiou, A. S., Bissonnette, R., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0029 · Cited by 215 · see citing works
The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review
Hadi, H. A., Tarmizi, A. I., Khalid, K. A., Gajdács, M., Aslam, A., & Jamshed, S. Q. (2021) · Life · doi:10.3390/life11090936 · Cited by 191 · see citing works
Peppers, J., Paller, A. S., Maeda-Chubachi, T., Wu, S., Robbins, K., Gallagher, K., & Kraus, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.047 · Cited by 165 · see citing works
The IL ‐13– OVOL 1– FLG axis in atopic dermatitis
Furue, K., Ito, T., Tsuji, G., Ulzii, D., Vu, Y. H., Kido‐Nakahara, M., Nakahara, T., & Furue, M. (2019) · Immunology · doi:10.1111/imm.13120 · Cited by 107 · see citing works
Gutermuth, J., Pink, A., Worm, M., Soldbro, L., Øland, C. B., & Weidinger, S. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20832 · Cited by 92 · see citing works
Wollenberg, A., Beck, L. A., de Bruin-Weller, M. S., Simpson, E. L., Imafuku, S., Boguniewicz, M., Zachariae, R., Olsen, C. K., & Thyssen, J. P. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20810 · Cited by 87 · see citing works
Mechanistic insights into the antipruritic effects of lebrikizumab, an anti–IL-13 mAb
Miron, Y., Miller, P. E., Hughes, C., Indersmitten, T., Lerner, E. A., & Cevikbas, F. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.028 · Cited by 59 · see citing works
Duggan, S. T. (2021) · Drugs · doi:10.1007/s40265-021-01583-1 · Cited by 55 · see citing works
Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review
Tier, H. L., Balogh, E. A., Bashyam, A. M., Fleischer, A. B., Spergel, J. M., Masicampo, E. J., Kammrath, L. K., Strowd, L. C., & Feldman, S. R. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00500-4 · Cited by 54 · see citing works
Pagan, A. D., David, E., Ungar, B., Ghalili, S., He, H., & Guttman‐Yassky, E. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.06.014 · Cited by 51 · see citing works
Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center
Dvořáková, V., O’Regan, G. M., & Irvine, A. D. (2017) · Pediatric Dermatology · doi:10.1111/pde.13209 · Cited by 45 · see citing works
Merola, J. F., Bagel, J., Almgren, P., Røpke, M. A., Lophaven, K. W., Vest, N. S., & Grewal, P. S. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.032 · Cited by 45 · see citing works
Sidbury, R., Alpizar, S., Laquer, V. T., Dhawan, S., Abramovits, W., Loprete, L., Krishnaswamy, J. K., Ahmad, F., Jabbar‐Lopez, Z. K., & Piketty, C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-021-00678-7 · Cited by 40 · see citing works
Greef, A. D., Ghislain, P., de Montjoye, L., & Baeck, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02490-5 · Cited by 35 · see citing works
Greef, A. D., Ghislain, P., Bulinckx, A., Coster, A., de Halleux, C., Damsin, T., Jacobs, M., Suys, E., Zoghaib, S., & Baeck, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01258-7 · Cited by 34 · see citing works
Impact of a Decade of Research Into Atopic Dermatitis
Arkwright, P. D., & Koplin, J. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.021 · Cited by 32 · see citing works
Rodríguez, J., Herranz, P., Ruíz‐Villaverde, R., Elosua‐González, M., Galán‐Gutiérrez, M., Figueras‐Nart, I., Miquel, J., de la Cueva, P., Serra‐Baldrich, E., Munera‐Campos, M., et al. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad153 · Cited by 31 · see citing works
Napolitano, M., D’Amico, F., Ragaini, E. M., Peyrin‐Biroulet, L., & Danese, S. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s340459 · Cited by 30 · see citing works
Pezzolo, E., & Naldi, L. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18753 · Cited by 29 · see citing works
Achten, R., Dekkers, C., Bakker, D. S., van Luijk, C., de Graaf, M., van Wijk, F., de Boer, J. H., de Bruin-Weller, M. S., & Thijs, J. L. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14305 · Cited by 23 · see citing works
Gargiulo, L., Ibba, L., Vignoli, C. A., Facheris, P., Valenti, M., Costanzo, A., & Narcisi, A. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2216815 · Cited by 22 · see citing works
Baverel, P., She, D., Piper, E., Ueda, S., Yoshioka, T., Faggioni, R., & Gevorkyan, H. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.12.001 · Cited by 18 · see citing works
Dermatology for the internist: optimal diagnosis and management of atopic dermatitis
Narla, S., & Silverberg, J. I. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2004322 · Cited by 17 · see citing works
Kelly, K. A., Perche, P. O., & Feldman, S. R. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s267217 · Cited by 16 · see citing works
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients
Guex‐Crosier, Y., Di‐Lucca, J., Häusermann, P., Laffitte, E., Saulīte, I., Schmid‐Grendelmeier, P., Schürch, K., Thormann, K., & Simon, D. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30020 · Cited by 15 · see citing works
Practical algorithm to inform clinical decision‐making in the topical treatment of atopic dermatitis
Luger, T. A., Adaskevich, U., Anfilova, M., Dou, X., Murashkin, N. N., Namazova-Baranova, L. S., Nitochko, O. I., Reda, A., Svyatenko, T. V., Tamay, Z., et al. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15921 · Cited by 12 · see citing works
Arnedo-Pena, A., Puig‐Barberà, J., Artero-Civera, A., Romeu-García, M. Á., Meseguer‐Ferrer, N., Fenollosa-Amposta, C., Vizcaíno-Batllés, A., Silvestre-Silvestre, E., Pac-Sa, M. R., Segura-Navas, L., et al. (2020) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2020.01.004 · Cited by 10 · see citing works
Review of Tralokinumab in the Treatment of Atopic Dermatitis
Singh, R., Taylor, A., Shah, M. A., Strowd, L. C., & Feldman, S. R. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221105686 · Cited by 10 · see citing works
Blauvelt, A., Gooderham, M., Bhatia, N. D., Langley, R. G. B., Schneider, S. K. R., Zoidis, J., Kurbasic, A., Armstrong, A. W., & Silverberg, J. I. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00805-y · Cited by 8 · see citing works
Association of atopic dermatitis with delinquent behaviors in US children and adolescents
Manjunath, J., Silverberg, N. B., & Silverberg, J. I. (2022) · Archives of Dermatological Research · doi:10.1007/s00403-021-02314-y · Cited by 4 · see citing works
Srivatsan, S., Floch-Ramondou, A. L., Nagashima, K. A., Buonagurio, B., Papatheodorou, A., Lim, W. K., Murphy, A. J., Sleeman, M. A., & Orengo, J. M. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.12.466 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45 · see citing works
Hagino, T., Uchiyama, A., Onda, M., Kosaka, K., Araki, T., Motegi, S., Saeki, H., Fujimoto, E., & Kanda, N. (2025) · Dermatitis · doi:10.1089/derm.2025.0004 · Cited by 18 · see citing works
IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents
Teixeira, C., Yilmaz, O., Bernardo, D., & Torres, T. R. (2024) · Journal of International Medical Research · doi:10.1177/03000605241286832 · Cited by 17 · see citing works
Hagino, T., Uchiyama, A., Kosaka, K., Araki, T., Saeki, H., Fujimoto, E., Motegi, S., & Kanda, N. (2025) · Dermatitis · doi:10.1177/17103568251361929 · Cited by 5 · see citing works
Yoneyama, M., Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025) · Dermatitis · doi:10.1089/derm.2025.0146 · Cited by 4 · see citing works
Okano, F., Hagino, T., Uchiyama, A., Kosaka, K., Araki, T., Saeki, H., Fujimoto, E., Motegi, S., & Kanda, N. (2025) · Dermatitis · doi:10.1177/17103568251380867 · Cited by 3 · see citing works
Hagino, T., Uchiyama, A., Saeki, H., Fujimoto, E., Motegi, S., & Kanda, N. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01033-2 · Cited by 3 · see citing works
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1 · see citing works
“Biologic therapies targeting type 2 inflammation, including dupilumab, lebrikizumab, and tralokinumab, have shown significant efficacy in moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling [11–15].”
Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab
Dattola, A., Tolone, M., Amore, E., Bennardo, L., Amato, S., Grieco, T., Richetta, A. G., Pellacani, G., Skroza, N., & Nisticò, S. P. (2024) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1403a204 · Cited by 1 · see citing works
Maldonado, R., Cohen, H., & Ray, S. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00786-7
- Authors
- Ewulu, A. R., Prajapati, S., & Feldman, S. R.
- Affiliations
- Wake Forest University Health Sciences (US)
- University of Southern Denmark (DK)
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2023-08-29
- Volume
- 15
- Issue
- 16
- Pages
- 1341-1349
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W4386245689
- Cited by
- 10
- References
- 38
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Funders
- Eli Lilly and Company
- GlaxoSmithKline/Stiefel
- AbbVie
- Janssen
- Alovtech
- vTv Therapeutics
- Bristol-Myers Squibb
- Samsung
- Pfizer
- Boehringer Ingelheim
- Amgen
- Dermavant
- Arcutis
- Novartis
- Novan
- Helsinn
- Sun Pharma
- Almirall
- Galderma
- Leo Pharma
- Mylan
- Celgene
- Ortho Dermatology
- Menlo
- Menlo, Merck & Co
- Qurient
- Forte
- Arena
- Biocon
- Accordant
- Argenx
- Sanofi
- Regeneron
- the National Biological Corporation
- Teladoc
- Micreos
- Eurofins
- Informa
- UpToDate
- the National Psoriasis Foundation
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- tralokinumab, atopic dermatitis, adolescents, moderate-to-severe atopic dermatitis, treatment efficacy, drug safety, adverse effects
- MeSH terms
- Adolescent, Adult, Antibodies, Monoclonal, Dermatitis, Atopic, Humans, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
